Reality Check: Biosimilar cheer for Biocon
The stock of Biocon surged as much as 16 per cent last Monday. This was after US drug regulator FDA approved Mylan’s Ogivri — a biosimilar version of Roche’s breast-cancer drug Herceptin.
Mylan and Biocon are partners for biosimilar products. Mylan will market Ogivri in the US, Europe and other key markets while Biocon will manufacture and supply the product on a cost-plus-profit sharing basis...
Read the rest of this article by Signing up for Portfolio.
It's completely free!
SIGN UP NOW
Investment alerts,End of day market reports, Market news analysis,External research reports and Technical calls
Daily update on Business and Market news via email
'Your Market Corner' Widget with personalized business and market news